Immunology
| 5 min read
Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence.
| 3 min read
Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity.
| 4 min read
Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need.
| 3 min read
Trained on more than 30,000 tumor genomes, MutationProjector offers drug developers a broader framework for connecting cancer genetics to therapy outcomes.
| 5 min read
A $15 million international study is investigating patients in long-term remission to understand whether lupus can truly switch off — and what that reveals about the immune system.
| 5 min read
Endometriosis is still largely managed with pain relief, hormones, and surgery, but a new precision peptide therapy seeks to directly target the underlying lesion biology.
| 2 min read
The collaboration combines VRG’s AI platform with AOP Health’s expertise in rare diseases and immunology to develop a highly selective therapeutic targeting Kv1.3-mediated immune dysfunction.
| 5 min read
Real-world data and late-stage trial results at DDW 2026 highlight persistent gaps in long-term IBD control despite therapeutic advances.
| 3 min read
New findings suggest that the location of mRNA expression in the body plays a critical role in shaping T cell responses, opening the door to more precise and effective mRNA-based treatments.
| 4 min read
Living drugs are blurring the line between therapy and biology, challenging decades of assumptions about how medicines are made and controlled.
| 5 min read
A single-batch bacterial system for producing nanobody cocktails could make snakebite treatment far more affordable and scalable.
| 4 min read
Executive orders, AI drug discovery models, pharmaceutical deals, and more led the news this week.
